A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK

Open to people ages 18 years and up

• Macular Edema Secondary to Inflammation (MESI) with a central subfield thickness (CST) of ≥400 microns on SD-OCT in Study Eye.
• Definitive presence of Intraretinal Fluid and/or Subretinal Fluid on SD-OCT in the Study Eye.
• BCVA ETDRS score of ≥25 and ≤70 letters (between 20/40 and 20/320 Snellen equivalent) in the Study Eye.
• Diagnosis of active or inactive non-infectious intraocular inflammation, acute or chronic in the Study Eye.

• Macular Edema in the Study Eye secondary to diabetic retinopathy, RVO, or wAMD.
• Active or suspected ocular or periocular infection in either eye.
• Any history of or active occlusive retinal vasculitis in either eye.